Leqembi has been shown in trials to slow the cognitive and functional decline of people in the early stages of Alzheimer’s disease.
How chat bots can actually detect Alzheimer’s disease
The approval of Leqembi was streamlined following the results of a study of 856 Alzheimer’s patients given a dose every two weeks, the FDA stated. “These results support the accelerated approval of Leqembi, which is based on the observed reduction of amyloid beta plaque, a marker of Alzheimer’s disease,” the agency announced.that showed the drug slowed cognitive and memory decline by around 27%., the FDA may approve drugs for serious conditions where there is an unmet medical need and drugs shown to have an effect that is “reasonably” likely to predict a clinical benefit to patients.
Leqembi is expected to cost around $25,000 annually per patient, Ivan Cheung, the U.S. chairman and CEO of Eisai,
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Read more »
Second Alzheimer’s treatment showing modest benefits for patients approved by FDAThe FDA has granted accelerated approval to a second Alzheimer’s drug that trial data show offers modest benefits to patients.
Read more »
Quantum Breakthrough: Light Source Produces Two Entangled Light BeamsOne potential application: Enhancing the sensitivity of atomic magnetometers used to measure the alpha waves emitted by the human brain. Scientists are increasingly seeking to discover more about quantum entanglement, which occurs when two or more systems are created or interact in such a manner
Read more »
Cancer Research Breakthrough: Scientists Create First Human Bone Marrow ‘Organoids’Researchers at Oxford University and the University of Birmingham have made a major breakthrough in cancer treatment by creating the first human bone marrow 'organoids' that accurately replicate the key features of human bone marrow. The technology, which is the subject of a patent application filed
Read more »
In a breakthrough, US approves world’s first vaccine for honeybeesThe US Department of Agriculture approved a conditional license for a vaccine for honeybees this week.
Read more »
FDA grants fast-track approval to experimental Alzheimer's drugThe FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.
Read more »